Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007138 (transitional cell carcinoma)
 3,949 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A total of 50 cases of primary tumors in the renal pelvis and ureter were treated in Tokyo University Branch Hospital (20 cases in 1966-1982) and in Tranomon Hospital (30 cases in 1977-1987). They were composed of 42 men and 8 women (5.3:1) with a mean age of 61 years. 31 patients suffered from renal pelvic tumors, 15 ureteral tumors and 4 tumors in both sites. The tumors were located in the left side in 33 cases, right in 16, and both sides in 1.86% of patients showed gross hematuria. The findings on IVP were filling defect (42%) and nonvisualization (33%). Positive urine cytology was obtained in 12 of 25 cases (48%). Surgery was performed in 47 cases. The remaining 3 cases were with advanced diseases. The surgeries were total nephroureterectomy plus ipsilateral retroperitoneal lymph node dissection in 26 cases, total nephroureterectomy without node dissection in 7, total nephroureterectomy and total cystectomy in 3, nephrectomy in 9, partial nephrectomy in 1 and segmental excision of ureter with ureteroureterostomy in one. Histologically, all tumors were transitional cell carcinoma. Over-all survival rates (Kaplan-Meier's method) of the operated patients at 1, 3, 5 years were 84.2%, 73.1% and 69.4%, respectively. The stage and grade of the tumors affected the prognosis. N factor at lymph node dissection was the most determining factor of prognosis. 3 advanced cases who did not receive surgery for primary site were treated with 5FU in 2, and with CAP in 1.2 of them died of the disease within 1 year after diagnosis, one patient was lost in follow up.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Treatment in 50 cases of transitional cell carcinoma in renal pelvis and ureter]. 221 65

A case of metastasis to the penis and the urethra from superficial bladder tumor of transitional cell carcinoma (TCC), grade 3 is reported. A 52-year-old male patient was diagnosed to have TCC of the urinary bladder (grade 3, stage pT1a) in May, 1985 and was treated initially with transurethral resection followed by adriamycin (ADR) instillation. In February, 1986, urethroscopy showed a papillary tumor in the cavernosal urethra and a metastatic tumor was noted in the corpus spongiosum penis. Biopsy of urethral tumor revealed TCC, grade 3. Therefore partial urethrectomy with resection of penile tumor was performed. Although the patient underwent combination chemotherapy involving CAP (cisplatin + ADR + cyclophosphamide) and M-VAC (methotrexate + vincristine + ADR + cisplatin) regimens, local lesion and metastatic lesions progressed, and he died in June 1986, 20 days after emasculation. The management of superficial bladder tumor with TCC, grade 3 was reviewed and discussed here.
 ...
PMID:[Penile and urethral metastases from superficial bladder tumor after TUR: a case report]. 280 93

The influence of cytotoxic chemotherapy on the number and function of peripheral neutrophils was studied in time sequence in 9 cancer patients; 6 patients with transitional cell carcinoma of urothelium treated with CAP, the combination of cyclophosphamide, adriamycin and cisplatin, and the other 3 with testicular tumor treated with PEB, the combination of cisplatin, etoposide and bleomycin. The neutrophil function was evaluated by the superoxide production, measuring chemiluminescence of the neutrophil suspension by a photometer. The peripheral neutrophil count (PNC) significantly (p < 0.01) decreased with the nadir count of 280 +/- 100/mm2 16.4 days after cytotoxic chemotherapy and recovered to the normal level by the next course. The neutrophil function declined significantly (p < 0.01) as PNC decreased, reached the minimum almost at the same time as PNC, and returned to the normal level by the next course. Of the 9 cases, the neutrophil function in 6 cases reached the minimum on the same day as that of PNC. The study shows that cytotoxic chemotherapy appears to impair the host defense mechanism in cancer patients not only in inducing neutropenia but also in deteriorating neutrophil function at the same time.
 ...
PMID:[Influence of cytotoxic chemotherapy on superoxide production by neutrophils in cancer patients]. 768 Jul 4

The in vivo effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the number and function of peripheral neutrophils were studied in time sequence in 9 cancer patients receiving anticancer cytotoxic chemotherapy; 6 patients with transitional cell carcinoma of urothelium treated with CAP (the combination of cyclophosphamide, adriamycin and cisplatin) and the other 3 with testicular tumor treated with PEB (the combination of cisplatin, etoposide and bleomycin). The neutrophil function was evaluated by superoxide production, measuring chemiluminescence of the neutrophil suspension by a photometer. In the 1st course, when no rhG-CSF was administered, the neutrophil function declined significantly (p < 0.01) as the peripheral neutrophil count (PNC) decreased, reached the minimum almost at the same day as PNC reached the nadir, and returned to the normal level at the beginning of the next course. In the 2nd course, when rhG-CSF (75 micrograms/body) was administered subcutaneously daily for 14 consecutive days beginning at 72 hours after the chemotherapy, the nadir of neutropenia was elevated (p < 0.01), the period of neutropenia (< 1,000/mm3) was shortened (p < 0.01), the recovery from neutropenia (> 1,500/mm3) was accelerated (p < 0.01) as compared to the 1st course, and an marked increase of PNC (p < 0.01) to the peak on the next day of the last administration of rhG-CSF was observed. In addition, deterioration of neutrophil function was alleviated (p < 0.05) and the neutrophil function was enhanced (p < 0.01-0.05) during rhG-CSF administration, even at the nadir of neutropenia.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Effects of recombinant human granulocyte colony-stimulating factor on superoxide production by neutrophil in cancer patients receiving chemotherapy]. 768 23

Conventional treatments such as surgery and radiotherapy for deeply invasive, clinically non-metastatic bladder cancer are associated with cure in less than 30% of cases. This has led to the search for new approaches to therapy. Based on the excellent results with combination chemotherapy such as M-VAC in patients with advanced disease, neoadjuvant or adjuvant chemotherapy has been advocated to improve survival. Twenty patients with primary invasive bladder cancer who underwent radical cystectomy received postoperative adjuvant chemotherapy using a CAP (cyclophosphamide, doxorubicin and cisplatin) or modified M-VAC (methotrexate, vinblastine, pirarubicin and cisplatin) regimen. Sixteen of the patients were treated with CAP and four with the modified M-VAC. Of the 20 patients, 17 had transitional cell carcinoma with or without non-transitional cell elements. All of the patients had tumors with a histological grade of G2 (six cases) or G3 (14 cases). As for lymph node metastasis, there were 10 N0 cases, three N1 cases, six N2 cases, and one N3 case. The five-year survival rate of these 20 patients was 65.9%, while that of 49 patients not administered any adjuvant chemotherapy was 29.9%. Regarding toxicity, both adjuvant chemotherapy regimens in this study were generally well tolerated. The most common toxic effects were gastrointestinal symptoms, alopecia and myelosuppression. Twenty other patients with invasive transitional cell carcinoma of the bladder received two or three cycles of neoadjuvant chemotherapy using the modified M-VAC or MEC (methotrexate, epirubicin and cisplatin) regimen prior to radical cystectomy or partial cystectomy. Of 19 evaluable patients who received neoadjuvant chemotherapy, a complete response was observed in two (10%), a partial response in 11 (55%), and no change in six (30%). The overall response rate was 65%. The five-year survival rate of 20 patients who received neoadjuvant chemotherapy was 74.2%. Regarding toxicity, one patient died of a bowel complication after surgery, and the complication was suggested to be drug-induced.
 ...
PMID:[Neoadjuvant and adjuvant chemotherapy of bladder cancer]. 798 16

We report 2 cases of primary malignant lymphoma arising in the urinary bladder. The first case was a 64-year-old woman complaining of gross hematuia during the follow-up period of transitional cell carcinoma (grade 2, stage pTa) of the bladder that was treated with TUR in 1989. Her bladder tumor of this time was broad based, not papillary, and situated on the right side wall with bleeding. The pathological diagnosis of transurethral biopsy specimens was non-Hodgkin lymphoma, diffuse large, B cell type. Four courses of CAP chemotherapy was so effective that she has been free of the disease up to now. The second was a 51-year-old woman presenting with painless gross hematuia. A solid, round and intramural tumor, which was recognized on the left side wall by cystoscopy, was resected endoscopically as much as possible. Three courses of VEPA chemotherapy was done because pathologically it was non-Hodgkin lymphoma, diffuse medium, B cell type, although no evidence of other tumors in any organs was fortunately detected with further examinations. She has been doing well without recurrence for 9 months after discharge from the hospital. Primary malignant lymphoma of the bladder is unusual. About 70 cases have been reported in foreign countries, but only 23 cases in Japan. When malignant lymphoma is confined to the bladder, radiation and chemotherapy can be curative, and yet preserve the function of the bladder.
 ...
PMID:[Primary malignant lymphoma of the urinary bladder]. 818 66

Fifty eight cases of primary tumors in the renal pelvis and ureter were treated at Toranomon Hospital between 1983 and 1992. They consisted of 32 renal pelvic tumors, 21 ureteral tumors and 5 tumors at both sites. The age of the patients ranged from 30 to 84 years (mean 63.1). Surgery was performed in 56 cases. Radical nephroureterectomy with concomitant ipsilateral retroperitoneal lymph node dissection was performed in 38 cases. The other surgeries were radical nephroureterectomy without lymph node dissection in 9, nephrectomy in 4, resection of ureter and reanastomosis in 3, radical nephroureterectomy and cystectomy in 1 and partial nephrectomy in 1. Pathologically, 53 were transitional cell carcinoma (TCC), 2 were TCC plus squamous cell carcinoma and 1 was TCC plus adenocarcinoma. Over-all survival rates (Kaplan-Meier) of 56 surgical cases at 1, 3, 5 years were 92.2, 83.7 and 72.8%, respectively. Combination chemotherapy (M-VAC or CAP) was performed in 9 cases of metastatic disease and 1 case of bilateral disease. Of these 10 cases, one achieved complete remission, 2 no change and 7 had progressive disease. Adjuvant chemotherapy was performed in 21 cases after surgery. These 21 patients were of high risk in recurrence either Grade 3 or pT3. However, the 5-year survival rate was 77.3% in these patients. Thus we conclude that the adjuvant chemotherapy in high risk patients was effective in our cases.
 ...
PMID:[Long-term results of surgical treatment for renal pelvic and ureteral tumors]. 853 70

Transitional cell carcinoma is a malignancy in which a number of single agents with different mechanisms of action are effective. Most older agents have limited activity, but several combinations are quite active. The most common regimens over the past 15 years were cyclophosphamide, doxorubicin, and cisplatin (CAP, CISCA); cisplatin, methotrexate, and vinblastine (CMV, MCV); and (methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC). Several new agents have been identified recently, including docetaxel, paclitaxel, gemcitabine, and ifosfamide. Combinations using these new agents now provide alternatives to the M-VAC combination that have much less toxicity and, in some instances, are used as multimodality therapy in patients with unresectable primary tumors without the degree of toxicity associated with older combinations of chemotherapy. Phase II and Phase III trials evaluating these new combinations are reviewed.
 ...
PMID:Chemotherapy agents in transitional cell carcinoma: the old and the new. 1124 30